ERBB2 and breast carcinoma: Currently, elevated creatinine levels are widely acknowledged as a frequent outcome in HR+, HER2-breast cancer patients undergoing CDK 4/6 inhibitor treatment and are generally considered reversible upon treatment cessation.46